<DOC>
	<DOCNO>NCT02850419</DOCNO>
	<brief_summary>The 105-15-201 study design assess effectiveness tolerability combination heat-activated target therapy ( radiotherapy + hyperthermia + lyso-thermosensitive liposomal doxorubicin ) loco-regional relapse breast cancer patient .</brief_summary>
	<brief_title>Heat-Activated Target Therapy Local-Regional Relapse Breast Cancer Patients</brief_title>
	<detailed_description>Locoregional recurrence breast cancer ( LRR ) mastectomy clinically challenge problem . Between 5 % 35 % woman operable breast cancer experience isolate LRR follow primary treatment , usually within 5 year initial mastectomy . LRR LR typically cause pain , lymphedema , and/or loss freedom movement . Therapeutic option usually involve resection , radiation , specialized center , combine radiation hyperthermia . However , local control remain suboptimal previously irradiate chest wall patient combination radiation hyperthermia provide local control rate 65 % . Lyso-thermosensitive liposomal doxorubicin ( LTLD ) temperature sensitive liposome systemically administer engineer selectively release doxorubicin content expose temperature ≥ 39.5°C . Local mild hyperthermia ( 40 44°C ) cytotoxic know immunomodulatory effect along radiation chemosensitizing effect heat tissue . Furthermore , mild hyperthermia enhances leakiness tumor tissue , increase local perfusion upregulates transvascular transport doxorubicin . Radiation therapy administer combination therapy . This study evaluate application tri-modal approach LTLD improve outcome : radiation , hyperthermia , target release novel formulation doxorubicin .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>1 . Histologically documented recurrent adenocarcinoma breast recurrence chest wall overlie skin : Ulcerative chest wall disease define nonhealing wound consistent cancer . Inflammatory breast carcinoma . Breast carcinoma resect medical reason . 2 . Tumor thickness , must clinically indicate hyperthermia therapy , measure clinical exam radiological imaging study ( CT MRI ) . The target local tumor lesion ( ) must able cover within two hyperthermia field treatment . 3 . LRR Disease progression despite available standard treatment option base clinically indicate accord investigator 's clinical medical judgment , include : one radiation treatment ( ) chest wall 4 . Patients stable distant bone metastasis ; concomitant treatment Zoledronic acid Denosumab allow 5 . Nonpregnant female least 18 year age . If subject childbearing age , must negative serum pregnancy test baseline must agree practice acceptable form birth control study . 6 . Provide write informed consent willing comply protocol requirement . 1 . No concomitant cytotoxic antineoplastic therapy allow . Prior chemotherapy administer within 5 halflives 28 day whichever shorter . 2 . Prior confirm allergic reaction ( include moderate rash , dyspnea , wheeze , urticaria symptom ) attribute administration either anthracyclines liposomally encapsulate drug require discontinuation prior therapy . 3 . Patients previously receive hyperthermia conjunction either radiation therapy chemotherapy . 4 . Previous treatment anthracyclines exceed follow dosage : free doxorubicin ( i.e . non liposomal ) and/or liposomal doxorubicin ≥300 mg/m2 epirubicin free &gt; 540 mg / m2 . 5 . Previous ( required active treatment within 5 year ) concomitant malignancy except basal cell cancer , situ carcinoma cervix , contralateral breast cancer . Subjects prior contralateral breast malignancy include receive chemotherapy . 6 . Baseline laboratory ( establish eligibility ) : · Granulocytes ... ... &lt; 1,500/ microliter · Platelets ... ... ... . &lt; 75,000/ microliter · Hemoglobin ... &lt; 9 gm/dL Total Bilirubin ... &gt; 2 mg/dL ALT AST ... &gt; 2.5X upper limit normal Creatinine ... ... ... &gt; 1.5 X upper limit normal . 7 . ECOG/Zubrod Performance Status &gt; 2 . 8 . MUGA/Echocardiogram Left Ventricular Ejection Fraction &lt; 50 % . 9 . History : acute coronary syndrome , cerebral vascular accident , abnormal cardiac stress test within last 6 month , symptomatic coronary artery disease , uncontrolled hypertension cardiomyopathy cardiac valvular surgery open heart surgery . 10 . Conditions may interfere hyperthermia portion trial : functioning cardiac pacemaker ; metal plate , rod prosthesis chest wall , breast reconstruction implant , severe numbness and/or tingle chest wall breast , skin graft and/or flap breast/CW . 11 . Serious active infection require longterm antibiotic treatment . 12 . Has receive external radiation therapy within 60 day prior study enrollment . 13 . Patients parenchymal know brain metastasis ; metastasis operate irradiated patient include study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>